Scottkuntz1
Contributor
I am not sure if using CPT code 79101 is the correct code or not? Thanks for any help that can be given.
74 y/o M with metastatic, castrate resistant prostate cancer on protocol 2016-120
using Xofigo with atezolzumab. Randomized to arm B (staggered dosing: 28-day radium-223
dichloride run-in): radium-223 dichloride
began on Day 1 of Cycle 1, and atezolizumab will begin on Day 1 of Cycle 2 (n =
10)
TECHNIQUE:
After explaining risks and benefits of Radium-223 dichloride (Xofigo) therapy for
painful bone metastatic disease to the patient, including radiation safety precautions,
and obtaining written and oral consent, the patient was administered 101.9 microCuries
of Ra-223 dichloride intravenously.
FINDINGS:
There were no apparent complications. The patient was instructed to follow up with
a repeat CBC with differential on 1/11/18 and has an apt for his next administration
on 1/17/2018 at 11:30 am
IMPRESSION:
101.9 microCuries of Ra-223 dichloride was administered for therapy of painful
bone metastases.
74 y/o M with metastatic, castrate resistant prostate cancer on protocol 2016-120
using Xofigo with atezolzumab. Randomized to arm B (staggered dosing: 28-day radium-223
dichloride run-in): radium-223 dichloride
began on Day 1 of Cycle 1, and atezolizumab will begin on Day 1 of Cycle 2 (n =
10)
TECHNIQUE:
After explaining risks and benefits of Radium-223 dichloride (Xofigo) therapy for
painful bone metastatic disease to the patient, including radiation safety precautions,
and obtaining written and oral consent, the patient was administered 101.9 microCuries
of Ra-223 dichloride intravenously.
FINDINGS:
There were no apparent complications. The patient was instructed to follow up with
a repeat CBC with differential on 1/11/18 and has an apt for his next administration
on 1/17/2018 at 11:30 am
IMPRESSION:
101.9 microCuries of Ra-223 dichloride was administered for therapy of painful
bone metastases.